Targeting Cholesterol Metabolism is A New Strategy to Overcome Chemotherapy Resistance in Pancreatic Cancer: National Cancer Institute Research | August 2026

Introduction:

Pancreatic ductal adenocarcinoma (PDAC) frequently develops resistance to chemotherapy through metabolic adaptations that enhance tumor survival. New research from the University of Oklahoma is investigating whether pancreatic cancer exploits cholesterol metabolism to withstand chemotherapy and whether disrupting this pathway could improve treatment response.

Why is this research important?

Chemotherapy resistance remains a major barrier to improving survival in PDAC.

Pancreatic cancer cells can reprogram their metabolism to survive therapeutic stress.

ZC3H15, an RNA-binding protein, has emerged as a potential regulator of cholesterol metabolism and treatment resistance.

Targeting this pathway could potentially enhance the effectiveness of existing chemotherapy.

Key Findings & Research Direction:

High tumor ZC3H15 expression was associated with chemotherapy resistance and poorer survival in preliminary studies.

ZC3H15 appears to stabilize KDM3A-related RNA, altering cholesterol metabolism and promoting epithelial-to-mesenchymal transition (EMT), a phenotype associated with tumor adaptability and metastatic potential.

The research will determine whether disrupting the ZC3H15–KDM3A–cholesterol axis can reverse this resistant tumor phenotype.

Importantly, investigators will test whether rosuvastatin combined with FOLFIRINOX can increase chemotherapy sensitivity in preclinical pancreatic cancer models.

Clinical Impact:

This work introduces cholesterol metabolism as a potentially druggable vulnerability in pancreatic cancer. The particularly attractive aspect is the possibility of repurposing rosuvastatin, a widely available cholesterol-lowering drug, to enhance FOLFIRINOX activity. However, this remains preclinical research, and clinical benefit has not yet been demonstrated.

Bottom Line:

Pancreatic cancer may exploit the ZC3H15–KDM3A pathway to reprogram cholesterol metabolism and survive chemotherapy. Targeting this metabolic adaptation—including potential rosuvastatin plus FOLFIRINOX therapy—offers an intriguing new strategy for overcoming treatment resistance that now requires experimental and ultimately clinical validation.